Immunome Net Worth
Immunome Net Worth Breakdown | IMNM |
Immunome Net Worth Analysis
Immunome's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunome's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunome's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunome's net worth analysis. One common approach is to calculate Immunome's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunome's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunome's net worth. This approach calculates the present value of Immunome's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunome's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunome's net worth. This involves comparing Immunome's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunome's net worth relative to its peers.
Enterprise Value |
|
To determine if Immunome is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunome's net worth research are outlined below:
| Immunome generated a negative expected return over the last 90 days | |
| Immunome has high historical volatility and very poor performance | |
| Immunome has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with loss before overhead, payroll, taxes, and interest of (81 M). | |
| Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a frail financial position based on the latest SEC disclosures | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: The Joint Corp. Matches Q4 Earnings Estimates |
Immunome uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunome. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunome's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immunome Target Price Consensus
Immunome target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immunome's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Immunome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immunome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immunome, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmunome Target Price Projection
Immunome's current and average target prices are 8.77 and 30.00, respectively. The current price of Immunome is the price at which Immunome is currently trading. On the other hand, Immunome's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Immunome Target Price
Know Immunome's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunome is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunome backward and forwards among themselves. Immunome's institutional investor refers to the entity that pools money to purchase Immunome's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jefferies Financial Group Inc | 2024-12-31 | 2 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.2 M | Woodline Partners Lp | 2024-12-31 | 980.9 K | Sofinnova Ventures | 2024-12-31 | 746.8 K | Point72 Asset Management, L.p. | 2024-12-31 | 688.8 K | Jpmorgan Chase & Co | 2024-12-31 | 648.6 K | Northern Trust Corp | 2024-12-31 | 516.5 K | Adage Capital Partners Gp Llc | 2024-12-31 | 500 K | T. Rowe Price Investment Management,inc. | 2024-12-31 | 5.5 M | Redmile Group, Llc | 2024-12-31 | 4.8 M |
Follow Immunome's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 742.6 M.Market Cap |
|
Project Immunome's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.02) | (1.08) |
When accessing Immunome's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunome's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunome's profitability and make more informed investment decisions.
Evaluate Immunome's management efficiency
Immunome has return on total asset (ROA) of (0.3989) % which means that it has lost $0.3989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7636) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of March 2025, Return On Tangible Assets is likely to drop to -0.68. In addition to that, Return On Capital Employed is likely to drop to -0.82. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 17th of March 2025, Other Current Assets is likely to grow to about 7.6 M, while Non Current Assets Total are likely to drop about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.44 | 5.71 | |
| Tangible Book Value Per Share | 5.44 | 5.71 | |
| Enterprise Value Over EBITDA | (3.67) | (3.85) | |
| Price Book Value Ratio | 1.59 | 0.82 | |
| Enterprise Value Multiple | (3.67) | (3.85) | |
| Price Fair Value | 1.59 | 0.82 | |
| Enterprise Value | 103.8 M | 109 M |
Leadership effectiveness at Immunome is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 49.8756 | Revenue | Quarterly Revenue Growth (0.18) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunome insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunome Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
| 4th of February 2025 Other Reports | ViewVerify | |
| 3rd of February 2025 Other Reports | ViewVerify | |
| 30th of January 2025 Other Reports | ViewVerify |
Immunome Earnings Estimation Breakdown
The calculation of Immunome's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Immunome is estimated to be -1.0375 with the future projection ranging from a low of -1.12 to a high of -0.975. Please be aware that this consensus of annual earnings estimates for Immunome is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.12 Lowest | Expected EPS | -0.97 Highest |
Immunome Earnings Projection Consensus
Suppose the current estimates of Immunome's value are higher than the current market price of the Immunome stock. In this case, investors may conclude that Immunome is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immunome's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 8 | 64.6% | -0.78 | -1.0375 | -7.94 |
Immunome Earnings per Share Projection vs Actual
Actual Earning per Share of Immunome refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Immunome predict the company's earnings will be in the future. The higher the earnings per share of Immunome, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Immunome Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Immunome, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Immunome should always be considered in relation to other companies to make a more educated investment decision.Immunome Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Immunome's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.56 | -0.78 | -0.22 | 39 | ||
2024-08-09 | 2024-06-30 | -0.39 | -0.49 | -0.1 | 25 | ||
2024-05-14 | 2024-03-31 | -0.69 | -2.51 | -1.82 | 263 | ||
2024-03-28 | 2023-12-31 | -0.28 | -4.22 | -3.94 | 1407 | ||
2023-11-09 | 2023-09-30 | -0.17 | -0.36 | -0.19 | 111 | ||
2023-08-09 | 2023-06-30 | -0.16 | -0.46 | -0.3 | 187 | ||
2023-05-05 | 2023-03-31 | 0.59 | -0.35 | -0.94 | 159 | ||
2023-03-16 | 2022-12-31 | -0.67 | -0.64 | 0.03 | 4 | ||
2022-11-14 | 2022-09-30 | -0.76 | -0.75 | 0.01 | 1 | ||
2022-08-05 | 2022-06-30 | -0.75 | -0.74 | 0.01 | 1 | ||
2022-05-12 | 2022-03-31 | -0.69 | -0.96 | -0.27 | 39 | ||
2022-03-28 | 2021-12-31 | -0.81 | -0.68 | 0.13 | 16 | ||
2021-11-15 | 2021-09-30 | -0.5 | -0.65 | -0.15 | 30 | ||
2021-08-16 | 2021-06-30 | -0.39 | -0.46 | -0.07 | 17 | ||
2021-05-12 | 2021-03-31 | -0.41 | -0.37 | 0.04 | 9 | ||
2021-03-25 | 2020-12-31 | -0.29 | -0.4 | -0.11 | 37 | ||
2020-11-16 | 2020-09-30 | -0.38 | -7.52 | -7.14 | 1878 | ||
2020-09-02 | 2020-06-30 | 0 | -0.58 | -0.58 | 0 |
Immunome Corporate Management
| Matthew Robinson | Chief Officer | Profile | |
| Michael Morin | Chief Scientist | Profile | |
| Philip Roberts | Chief Officer | Profile | |
| Robert Lapetina | Principal Officer | Profile | |
| JD Esq | General Officer | Profile | |
| Purnanand Sarma | CEO Pres | Profile | |
| Sandra Esq | Gen Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.